A farkon watan Agusta, INNOVITA 2019-nCoV antigen gwajin an amince da shi daga Hukumar Kare Magunguna da Kayayyakin Lafiya ta Faransa (ANSM) da Hukumar Abinci da Magunguna ta Thailand (Thai FDA), a lokacin, gwajin INNOVITA Covid-19 ya yi rajista a kusan 30. kasashe.
Wadannan kasashe sun hada da China, Amurka, Brazil, Faransa, Italiya, Rasha, Spain, Portugal, Netherlands, Hungary, Austria, Sweden, Singapore, Philippines, Malaysia, Thailand, Argentina, Ecuador, Colombia, Peru, Chile, Mexico , da sauransu. A halin yanzu, INNOVITA kuma tana neman takardar shedar CE da rajista na US FDA COVID-19 antigen test, don hanzarta faɗaɗa sikelin rajista na ketare na kayan gwajin COVID-19.
Bayan fitar da shi zuwa ƙasashen da ke sama, INNOVITA tana ba da ingantaccen, sauri da kuma babban bincike na cututtukan COVID-19 ya taka muhimmiyar rawa a yaƙi da COVID-19 a kowace ƙasa.
Bayan barkewar COVID-19 a cikin 2020, INNOVITA ta ba da amsa cikin sauri tare da tura manyan jami'an R&D don gudanar da binciken kimiyya dare da rana, kuma ta sami nasarar haɓaka kayan gwajin ƙwayar cuta na coronavirus (2019-nCoV) kuma NMPA ta amince da su.INNOVITA na daga cikin kamfanoni na farko a kasar Sin da suka sami takardar shaidar rajista na kayan gwajin rigakafin COVID-19.Kayayyakin yanzu ana sayar da su sosai a cikin gida da waje, suna ba da gudummawa sosai wajen yaƙar cutar.A cikin Satumba 2020, an ba INNOVITA lambar yabo ta “National Advanced Collective” a cikin taron yabo na ƙasa don yaƙar cutar ta COVID-19.A ranar 26 ga Janairu, 2021, Ma'aikatar Kimiyya da Fasaha ta kuma aika da wasiƙar godiya ga INNOVITA don tallafi a cikin aikin bincike na gaggawa don yaƙar cutar.
A nan gaba, INNOVITA za ta ci gaba da cin gajiyar fa'idar fasaharta da ingancinta, da yin bincike kan kasuwannin duniya, da ba da gudummawar Sin Ƙarfinta wajen yaƙar annobar a duniya!
Lokacin aikawa: Oktoba 18-2021